Elsevier

Drug and Alcohol Dependence

Volume 152, 1 July 2015, Pages 139-146
Drug and Alcohol Dependence

Full length article
Substance use and treatment of substance use disorders in a community sample of transgender adults

https://doi.org/10.1016/j.drugalcdep.2015.04.008Get rights and content

Highlights

  • This is the first study of risks for substance use/substance use disorder (SUD) treatment in transgender men and women.

  • We assessed psychosocial risk factors for substance use and SUD treatment in transgender adults.

  • Substance use and SUD treatment are linked to age, education, poverty and male-to-female identity.

  • Substance use and SUD treatment are linked to violence/PTSD, discrimination, housing and sex work.

  • SUD treatment should incorporate psychosocial/structural approaches for transgender adults.

Abstract

Background

Transgender people have elevated substance use prevalence compared with the U.S. general population, however no studies have comprehensively examined the relationship of psychosocial risk factors to substance use and substance use disorder (SUD) treatment among both male-to-female (MTF) and female-to-male (FTM) transgender adults.

Methods

Secondary data analysis of a 2013 community-based survey of transgender adults in Massachusetts (N = 452) was conducted. Adjusted multivariable logistic regression models were fit to examine the relationship of four risk factor domains with SUD treatment history and recent substance use: (1) demographics; (2) gender-related characteristics; (3) mental health; (4) socio-structural factors. Adjusted Odds Ratios (aOR) and 95% Confidence Intervals (95% CI) were estimated.

Results

Ten percent of the sample reported lifetime SUD treatment. Factors associated with significant increase in odds of lifetime SUD treatment alongside recent substance use (all p < 0.05) were: (1) older age (aOR = 1.02; 95% CI = 1.01–1.04), higher educational attainment (aOR = 3.59; 95% CI = 2.35–5.50), low income (aOR = 0.58; 95% CI = 0.39–0.86); (2) MTF identity (aOR = 3.03; 95% CI = 1.95–4.67), gender-affirming medical care (aOR = 1.99; 95% CI = 1.32–3.00); (3) intimate partner violence (aOR = 1.68; 95% CI = 1.13–2.49), posttraumatic stress disorder (aOR = 2.56; 95% CI = 1.69–3.88), depression (aOR = 2.30; 95% CI = 1.58–3.35), mental health treatment (aOR = 1.65; 95% CI = 1.11–2.45); (4) discrimination (aOR = 1.90; 95% CI = 1.22–2.95), unstable housing (aOR = 1.80; 95% CI = 1.21–2.67), and sex work (aOR = 2.48; 95% CI = 1.24–4.95).

Conclusions

Substance use and SUD treatment among transgender adults are associated with demographic, gender-related, mental health, and socio-structural risk factors. Studies are warranted that identify SUD treatment barriers, and integrate SUD treatment with psychosocial and structural interventions for a diverse spectrum of transgender adults.

Introduction

The term transgender describes people whose gender expression or identity differs from that traditionally attributed to their assigned natal sex (Mayer et al., 2008). Nearly 1 million American adults currently identify as transgender (Stroumsa, 2014). Studies examining substance use disorders (SUDs) among transgender people are rare, and reporting of gender identity data (e.g., transgender status) in SUD-related research is limited (Flentje et al., 2015). In the few studies that exist, transgender people have significantly elevated prevalence of alcohol and illicit drug use compared with the general population (Benotsch et al., 2013, Clements-Nolle et al., 2001, Herbst et al., 2008, Kecojevic et al., 2012, Reback and Fletcher, 2014, Santos et al., 2014).

A biopsychosocial model of illness (Engel, 1980) is often applied to understand SUDs, including consideration of the relationship of demographic, gender-related, mental health, and socio-structural risk factors to substance use and SUD treatment (Cheatle and Gallagher, 2006, Chermack and Giancola, 1997, Comfort and Kaltenbach, 1999, Griffiths, 2005, Marlatt, 1992). To our knowledge, however, no reports have comprehensively examined these factors in substance use and SUD treatment utilization among transgender adults. Indeed, the association between demographic characteristics and substance use among transgender people has not yet been well characterized. Studies have often focused on youth rather than the entire adult lifespan (Garofalo et al., 2006, Kecojevic et al., 2012, Rowe et al., 2015). In addition, gender differences in SUD treatment utilization between transgender people on the male-to-female spectrum (MTF/transgender women) vs female-to-male spectrum (FTM/transgender men) have not been described, as existing reports have focused primarily on substance use among transgender women in the context of HIV risk (Nemoto et al., 2004, Nuttbrock et al., 2014b, Reback and Fletcher, 2014, Rowe et al., 2015, Santos et al., 2014). Moreover, reporting of non-binary gender identity (i.e., gender identity which is not defined as either male or female, and may be defined as “genderqueer” or “gender variant”) in published substance use research is minimal (Flentje et al., 2015), and differences in substance use and SUD treatment between transgender people with binary vs non-binary gender identity have not been investigated.

Based on sexual minority (Meyer, 2003) and gender minority (Hendricks and Testa, 2012, Reisner et al., 2014a, Reisner et al., 2014d) stress theories, SUDs among transgender people are increasingly viewed as downstream consequences of internalized and enacted transphobia (Nuttbrock et al., 2014b). Transgender people are at high risk for verbal, physical and sexual victimization (Garofalo et al., 2006, Operario and Nemoto, 2010, Stieglitz, 2010, Stotzer, 2009). A national study of more than 6000 transgender people found that 63% had experienced a serious act of discrimination (e.g., medical service denial, eviction, bullying, or physical/sexual assault; Grant et al., 2011). Transgender people who, due to physical attributes that reveal their transgender status, are unable to “pass” (i.e., to be societally affirmed in the gender with which they identify) may be particularly vulnerable to victimization (Grant et al., 2011, Nemoto et al., 2004, Operario and Nemoto, 2010). Experiencing psychological or physical abuse as a result of one's nonconforming gender expression or identity is associated with a three- to four-fold higher odds of alcohol, marijuana, or cocaine use, as well as an 8-times higher odds of any drug use, among transgender women (Nuttbrock et al., 2014b). Among MTF transgender youth, gender-related discrimination is associated with increased odds of alcohol and drug use (Rowe et al., 2015). Research suggests that substance use may be a means of coping with discrimination, as a national study found that 35% of transgender people who experienced school-related verbal harassment, physical assault, sexual assault, or expulsion reported using substances to cope with transgender- or gender nonconformity-related mistreatment (Grant et al., 2011).

In the context of such common interpersonal trauma, a recent report showed that posttraumatic stress disorder (PTSD) symptoms are associated with increased odds of drug use among MTF youth (Rowe et al., 2015). Previous research also indicates that transgender people have high prevalence of depression (Clements-Nolle et al., 2001, Reisner et al., 2015) and, among transgender women, gender nonconformity-related abuse has been associated with higher likelihood of major depression (Nuttbrock et al., 2014a). Moreover, depression has been shown to mediate the relationship of gender-related abuse to substance use (Nuttbrock et al., 2014b). Though the associations of violent victimization, PTSD, and depression to substance use and SUD treatment utilization are well characterized in non-transgender populations (Davis et al., 2008, Jacobsen et al., 2001), these relationships remain largely unstudied among both MTF and FTM transgender adults.

Transgender people are twice as likely to be unemployed as non-transgender people (Grant et al., 2011), as stigma and discrimination restrict access to employment and income (Grant et al., 2011). Some transgender people, particularly transgender women, engage in sex work (Garofalo et al., 2006, Nemoto et al., 2006, Operario et al., 2008, Sausa et al., 2007, Sevelius et al., 2009). Sex work has been linked to increased prevalence and frequency of substance use among transgender women (Nuttbrock et al., 2014b). Little is known, however, about the associations of poverty, homelessness, and sex work to substance use and SUD treatment utilization among both MTF and FTM transgender adults, though these relationships have been studied extensively in non-transgender populations (Bassuk et al., 1998, Fischer and Breakey, 1991, Nuttbrock et al., 2004, Robertson et al., 1997, Shannon et al., 2008).

Many transgender people seek out medical gender affirmation technologies, such as cross-sex hormone therapy or surgeries, to align their physical selves with their internal sense of gender identity or expression. The American Medical Association has deemed cross-sex hormone therapy and gender-affirming surgery necessary medical treatments for gender dysphoria, defined as extreme and persistent distress related to incongruence of gender identity and natal sex (American Medical Association, 2008). Nevertheless, transgender individuals face numerous barriers to receiving appropriate gender-affirming health care (Operario and Nemoto, 2010), including a lack of both competent providers and insurance coverage (Operario and Nemoto, 2010, Sanchez et al., 2009, Spicer, 2010, Stroumsa, 2014). The psychological stress of health care access disparities faced by transgender people is believed to contribute to worse mental health (Poteat et al., 2013), including disproportionate substance use as a coping strategy (Wilson et al., 2015). A recent study examined the relationship of gender-affirming medical services to recent alcohol and drug use among transgender women (Wilson et al., 2015), however, the sample did not include transgender men, and SUD treatment utilization was not assessed. Thus research exploring the specific relationship of cross-sex hormone therapy and/or gender-affirming surgery to substance use and SUD treatment utilization among diverse groups of transgender people is warranted.

Significant gaps exist in the literature regarding the association of demographic, gender-related, mental health, and socio-structural risk factors to substance use and SUD treatment among transgender adults. To address these gaps, the present study aimed to: (1) assess the prevalence and distribution of SUD treatment history and recent substance use in a community sample of transgender adults; and (2) examine the relationship of substance use and SUD treatment utilization to demographic, gender-related, mental health, and socio-structural risk factors in this understudied and highly vulnerable population.

Section snippets

Participants and sampling

Data were gathered through Project VOICE, a community-based sample of 452 self-identified transgender and gender-nonconforming Massachusetts residents, ages 18 to 75 years. Participants were purposively recruited using bimodal methods (online and in-person) from August to December, 2013 and asked to complete a one-time survey assessing demographics, experiences of discrimination and victimization, and health indicators. Participants provided informed consent before beginning the survey. The

Sample characteristics

Characteristics of the study sample are presented in Table 1. The mean age was 33.6 (SD = 12.8) years, with 20.6% of the sample identifying as people of color and 36.9% self-identifying as MTF. Overall, 10% reported a lifetime SUD treatment history, whereas 7.3% reported both lifetime SUD treatment and recent substance use. Binge drinking in the past 3 months (47.0%) was reported more frequently than marijuana use (39.6%) or non-marijuana illicit drug use (19.0%) in the past 12 months. Recent

Discussion

In this community sample of transgender adults, the prevalence of alcohol and drug use was found to be consistent with previous studies assessing substance use in transgender people (Benotsch et al., 2013, Clements-Nolle et al., 2001, Herbst et al., 2008, Kecojevic et al., 2012, Reback and Fletcher, 2014, Santos et al., 2014). The higher prevalence of lifetime SUD treatment mainly among participants with recent illicit use of prescription medications such as stimulants, downers, and painkillers

Role of funding source

This project was supported with funding from the Miller Foundation. Dr. Keuroghlian is supported by the Kraft Family National Center for Leadership and Training in Community Health. Dr. Reisner is partly supported by grant R01 MH094323 from the National Institute of Mental Health. Dr. Weiss is supported by grant K24DA022288 from the National Institute on Drug Abuse. Ms. White is supported by grants T32MH020031 and P30MH062294 from the National Institute of Mental Health.

Funding sources had no

Contributors

All authors contributed to the interpretation of the data and revising the manuscript for important intellectual content. ASK led the drafting of the manuscript and oversaw subsequent revisions. SLR and ASK conceived the data analysis plan. SLR undertook the statistical analyses. SLR and JMW were principal investigators for Project VOICE, which they helped conceive and design. RDW provided clinical guidance for the article and edited the manuscript.

Conflict of interest

No conflict declared.

Acknowledgements

The authors would like to thank the participants of Project VOICE for taking part in the study.

References (72)

  • S.L. Reisner et al.

    Mental health of transgender youth in care at an adolescent urban community health center: a matched retrospective cohort study

    J Adolesc. Health

    (2015)
  • M.L. Rekart

    Sex-work harm reduction

    Lancet

    (2005)
  • C. Rowe et al.

    Prevalence and correlates of substance use among trans*female youth ages 16–24 years in the San Francisco Bay Area

    Drug Alcohol Depend.

    (2015)
  • K. Shannon et al.

    Social and structural violence and power relations in mitigating HIV risk of drug-using women in survival sex work

    Soc. Sci. Med.

    (2008)
  • K.A. Stieglitz

    Development, risk, and resilience of transgender youth

    J. Assoc. Nurses AIDS Care

    (2010)
  • R.L. Stotzer

    Violence against transgender people: a review of United States data

    Aggress. Violent Behav.

    (2009)
  • American Medical Association

    Resolution 122—Removing Financial Barriers to Care for Transgender Patients

    (2008)
  • A. Auldridge et al.

    Improving the Lives of Transgender Older Adults: Recommendations for Policy and Practice

    (2012)
  • E.L. Bassuk et al.

    Prevalence of mental health and substance use disorders among homeless and low-income housed mothers

    Am. J. Psychiatry

    (1998)
  • J. Brennan et al.

    Syndemic theory and HIV-related risk among young transgender women: the role of multiple, co-occurring health problems and social marginalization

    Am. J. Public Health

    (2012)
  • Centers for Disease and Control and Prevention

    Behavioral Risk Factor Surveillance System Questionnaire

    (2011)
  • M.D. Cheatle et al.

    Chronic pain and comorbid mood and substance use disorders: a biopsychosocial treatment approach

    Curr. Psychiatry Rep.

    (2006)
  • K. Clements-Nolle et al.

    HIV prevalence, risk behaviors, health care use, and mental health status of transgender persons: implications for public health intervention

    Am. J. Public Health

    (2001)
  • A.L. Coker et al.

    Frequency and correlates of intimate partner violence by type: physical, sexual, and psychological battering

    Am. J. Public Health

    (2000)
  • S.E. Collins et al.

    Project-based housing first for chronically homeless individuals with alcohol problems: within-subjects analyses of 2-year alcohol trajectories

    Am. J. Public Health

    (2012)
  • M. Comfort et al.

    Biopsychosocial characteristics and treatment outcomes of pregnant cocaine-dependent women in residential and outpatient substance abuse treatment

    J. Psychoactive Drugs

    (1999)
  • L. Davis et al.

    Major depression and comorbid substance use disorders

    Curr. Opin. Psychiatry

    (2008)
  • G.L. Engel

    The clinical application of the biopsychosocial model

    Am. J. Psychiatry

    (1980)
  • P.J. Fischer et al.

    The epidemiology of alcohol, drug, and mental disorders among homeless persons

    Am. Psychol.

    (1991)
  • K.I. Fredriksen-Goldsen et al.

    Physical and mental health of transgender older adults: an at-risk and underserved population

    Gerontologist

    (2014)
  • J.C. Gfroerer et al.

    Substance use in the US college-age population: differences according to educational status and living arrangement

    Am. J. Public Health

    (1997)
  • B.F. Grant et al.

    Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions

    Arch. Gen. Psychiatry

    (2004)
  • J.M. Grant et al.

    Injustice at Every Turn: A Report of the National Transgender Discrimination Survey

    (2011)
  • M. Griffiths

    A ‘components’ model of addiction within a biopsychosocial framework

    J. Subst. Use

    (2005)
  • M. Hendricks et al.

    A conceptual framework for clinical work with transgender and gender nonconforming clients: an adaptation of the Minority Stress Model

    Prof. Psychol. Res. Pract.

    (2012)
  • J.H. Herbst et al.

    Estimating HIV prevalence and risk behaviors of transgender persons in the United States: a systematic review

    AIDS Behav.

    (2008)
  • Cited by (152)

    View all citing articles on Scopus
    View full text